Table 4 Group 3: immunohistochemical expression of TOPK (patchy or diffuse) and association with clinicopathological and molecular features in hereditary Lynch syndrome-associated colorectal cancers
Group 3 ( N (%)) | |||
|---|---|---|---|
Clinicopathological features | Patchy | Diffuse | P -value |
Gender | |||
Female | 22 (53.7) | 18 (60.0) | 0.635 |
Male | 19 (46.3) | 12 (40.0) | |
Tumour location | |||
Left sided | 18 (46.2) | 11 (39.3) | 0.21 |
Right sided | 12 (30.7) | 14 (50.0) | |
Rectum | 9 (23.1) | 3 (10.7) | |
pT stage | |||
pT1–2 | 12 (31.6) | 2 (6.9) | 0.014 |
pT3–4 | 26 (68.4) | 27 (93.1) | |
pN stage | |||
pN0 | 23 (65.7) | 14 (51.9) | 0.27 |
pN1–2 | 12 (34.3) | 13 (48.2) | |
pM stage | |||
pM0 | 14 (70.0) | 5 (55.6) | 0.675 |
pM1 | 6 (30.0) | 4 (44.4) | |
Tumour grade | |||
G1–2 | 24 (72.7) | 18 (64.3) | 0.478 |
G3 | 9 (27.3) | 10 (35.7) | |
KRAS | |||
Wild type | 28 (68.3) | 20 (61.0) | 1.0 |
Mutation | 13 (31.7) | 9 (31.0) | |
BRAF | |||
Wild type | 38 (100.0) | 28 (96.6) | 0.433 |
Mutation | 0 (0.0) | 1 (3.5) | |
KRAS/BRAF | |||
Both wild type | 28 (68.3) | 19 (65.5) | 1.0 |
KRAS or BRAF mutation | 13 (31.7) | 10 (34.5) | |
Microsatellite status | |||
Stable/low | |||
High | 41 (57.3) | 30 (42.3) | 0.192 |
Mean (min, max) | |||
Age (years) | |||
Mean, range | 45.3, 24–73 | 47.4, 27–83 | 0.492 |
Rate (95% CI) | |||
5-year survival time | |||
All patients | 87.5 (73–95) | 88.7 (69–96) | 0.66 |
